Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Health Care M&A Weekly Deals, The Week Ending February 16, 2018
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Biotechnology Acquirer Target Price Bioverativ Inc. License to lentiviral vectors $5 million Oncologie, Inc. Exclusive license to lefitolimod $369 million Lee’s Pharmaceutical Limited Exclusive rights to GCC-4401C N/A Bristol-Myers... Read More »
Q4:2017 Health Care Spending, by Sector and Share
A total of $114.4 billion was spent to fund the 377 transactions reported in Q4:17, based on disclosed prices. The Managed Care sector dominated the dollar side of deal making, accounting for 70% ($80.6 billion) of spending. A single deal accounted for 67% of the quarter’s total, as CVS Health (NYSE: CVS) announced its agreement to acquire Aetna Inc. (NYSE: AET) for $77.0 billion (including debt). If that deal doesn’t close, this chart will look very different. The rest of the healthcare sectors were relegated to single-digit shares of the fourth quarter’s spending pie. The Pharmaceutical sector contributed 6% of the quarter’s total, with $6.9 billion, followed by Biotechnology (5%... Read More »
Hospital Deals in 2018: 27% for Critical Access Hospitals
2018 is still quite young, as we are writing in mid-February. Fifteen hospital mergers or acquisitions have reached the definitive agreement stage, which is when we consider them far enough along to include in our DealSearchOnline.com database. (If the deal falls apart later in due diligence or other process, it’s removed from the data.) Of the 15 hospital deals announced so far, four (27%) were for stand-alone critical access hospitals (CAHs). That percentage will change, of course, as the year goes on. But consider 2017. Of the 74 U.S. hospital transactions announced, seven (9%) targeted a critical access hospital. For all the discussion of rural and community hospitals seeking... Read More »
Roche Deal for Flatiron Health Builds its Oncology Muscle
Roche (SIX: RO) couldn’t let a good startup slip away. The Swiss drug maker announced it will pay $1.9 billion to keep New York City-based Flatiron Health, Inc. from going public. When it was founded in 2012, Flatiron’s goal was to gather and analyze data on cancer treatments and sells software based on those insights to help researchers develop drugs more quickly, and with more targeted precision. Toward that end, the company produced an oncology-specific electronic health record (EHR). It currently partners with more than 265 community cancer clinics, six major academic research centers and 14 out of the top 15 therapeutic oncology companies. Roche already holds a 12.6% stake... Read More »
Charles River Labs Adds MPI Research
The CRO deals just keep coming. Four have been announced since the beginning of the year, targeting contract research organizations (CROs). The latest announcement came from Charles River Laboratories International (NYSE: CRL), which is paying $800 million for Mattawan, Michigan-based MPI Research. This is the highest disclosed price for an acquisition by Charles River since 2011. MPI is a premier non-clinical contract research organization (CRO) that provides comprehensive testing services to biopharmaceutical and medical device companies worldwide. Its acquisition enhances Charles River’s ability to partner with clients across the drug discovery and development continuum. This... Read More »Health Care M&A Weekly Deals, The Week Ending February 9, 2018
We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Biotechnology Acquirer Target Price Roivant Sciences Exclusive license to derazantinib $3 million eHealth Acquirer Target Price Varian Medical Systems, Inc. Mobius Medical Systems N/A Pamlico Capital Office Practicum N/A Home Health Care... Read More »
Medical Staffing M&A Makes a Comeback
Labor shortages for physicians and nurses may heat up the medical staffing market in 2018. Through the first 10 days of February, three transactions for these service companies have been announced. Last year, 16 transactions targeting medical staffing services were made public, the highest number of deals in this segment since 2005 (19 deals) and 2004 (20). The most recent deal announcement came from Medical Solutions, a portfolio company of TPG Growth based in Omaha, Nebraska. Medical Solutions is a healthcare staffing firm that specializes in placing registered nurses in temporary travel assignments throughout the country. The target, PPR Travel Nursing, was a division of PPR Talent... Read More »
Managed Care Sector Had a Big Q4:17
The fourth quarter of 2017 will be remembered for some time to come, thanks to the game-changing deal announced between pharmacy/retailer CVS Health and Aetna, one of the largest managed care companies in the country. That was only one deal, of course, and there were actually 10 transactions announced in Q4:17. Fourth quarter deal volume represents a 38% share of the 26 deals announced in the previous 12 months, and a 150% increase over the same quarter in 2016. Source: HealthCareMandA.com, January 2018 Two of the 10 deals disclosed prices in the fourth quarter, for nearly $80.6 billion, the highest ever recorded in this sector, or several others. The total represents 95% of the $84.7... Read More »
Tax Overhaul Boosted Pharma Deals in Q4:17
The dam broke in the fourth quarter of 2017, and pharmaceutical deal makers began acquiring again. The Republican tax overhaul that lowered the tax rate for corporations’ repatriated cash was approved in December, spurring big drug companies to think about mergers and acquisitions once again. Deal volume in the fourth quarter shot up 100% over the previous quarter, to 34 transactions. Q4:17 basically equaled the same quarter in 2016, when 33 deals were announced. This quarter’s deal volume accounts for 35% of the 96 deals announced in the previous 12 months. Source: HealthCareMandA.com, January 2018 Twenty of the 34 announced transactions disclosed a price, making for a total of $6.9... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
